Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s Approval for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

 Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s Approval for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Roche’s Hemlibra Receives EU’s Approval for Severe Haemophilia A without Factor VIII Inhibitors

Shots:

  • The approval is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT as monothx. in 403 patients in ratio (1:1) with (ES-SCLC)
  • The P-III IMpower133 study results: mOS (12.3 vs 10.3 mos.); PFS (5.2 vs 4.3 mos.); safe & effective results with improvement in survival rates
  • Tecentriq is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptor and is evaluated in nine P-III trial for lungs & has received FDA & EU’s approval combining Avastin(bevacizumab)+ paclitaxel + carboplatin & Avastin for metastatic nonsqNSCLC respectively

Click here to read full press release/ article | Ref: Roche | Image: Carrauterie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post